Terbinafine Treatment of Axial Spondyloarthropathy
Trial Snapshot
- Phase
- Early Phase 1
- Status
- Withdrawn
- Locations
- 1
- Primary Endpoint
- Change in BASDAI score
Study Overview
Brief Summary
This is a pilot study to determine if further research is warranted to assess if anti-fungal therapy is an effective adjunctive treatment for axial spondyloarthropathy
Detailed Description
The purpose of this trial is to determine if terbinafine is an effective therapy for ankylosing spondylitis. Benefit will be determined by a reduction of the BASDAI by two or more.
The primary endpoint is the BASDAI at the completion of 16 weeks of terbinafine versus the BASDAI at the start of the trial and at the completion of the placebo. The secondary endpoint with the percent of patients whose BASDAI improves by two or more while on terbinafine (week 16) versus the percent of subjects with a similar improvement after 16 weeks of placebo.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Subjects age 18 and older of either sex will be included.
- •Subjects must be willing and able to provide informed consent.
- •Subjects must have been diagnosed with ankylosing spondylitis, axial spondyloarthritis, psoriatic spondylitis or spondylitis secondary to inflammatory bowel disease by a physician and must be willing to request records to validate the diagnosis.
- •Subjects must complete a symptom questionnaire called a BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) and must have a score of four or above to indicate active disease and the potential to improve.
- •Subjects must agree to remain on a stable treatment regimen for their joint disease for the duration of the trial and for one month before the study begins.
- •Subjects must be willing to provide stool samples and be willing to have routine lab studies every 8 weeks during the duration of the study.
Exclusion Criteria
- •Pregnant or lactating women will not be included.
- •Subjects must not be allergic or intolerant to terbinafine.
- •Subjects must not be taking medications that have the potential for serious interactions with terbinafine. These drugs include desipramine, cimetidine, fluconazole, cyclosporine and rifampin.
- •Subjects must not have taken antibiotics within 3 months of starting the study drug and collecting the baseline stool specimen.
- •Subjects with the following blood dyscrasias will not be included:
- •Hemoglobin <9g/dL or Hematocrit <30% White blood cell count <3.0 K/cu mm Absolute neutrophil count <1.2 K/cu mm Platelet count <100 K/cu mm Subjects with an estimated GFR ≤50 ml/min Subjects with a total bilirubin, AST, or ALT more than 1.5 times the upper limit of normal at screening.
- •Severe, progressive, or uncontrolled chronic liver disease including fibrosis, cirrhosis, or recent or active hepatitis.
- •History of any lymphoproliferative disorder such as Epstein Barr virus (EBV) related lymphoproliferative disorder, history of lymphoma, leukemia, or signs and symptoms suggest of current lymphatic disease.
- •Current malignancy or history of malignancy, with the exception of adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin, or cervical carcinoma in situ.
- •Have or have had an opportunistic infection (e.g., herpes zoster [shingles], cytomegalovirus, Pneumocystis carinii, aspergillosis and aspergilloma, histoplasmosis, or mycobacteria other than TB) within 6 months prior to screening.
- •Have a known infection with human immunodeficiency virus (HIV)
- •Have current signs and symptoms of systemic lupus erythematosus, or severe, progressive, or uncontrolled renal, hepatic, hematologic, endocrine, pulmonary, cardiac (New York Heart Association class III or IV), neurologic, or cerebral diseases.
Arms & Interventions
Drug to Placebo
Subjects will begin treatment on study drug then crossover to placebo.
Intervention: Laboratory Testing (Diagnostic Test)
Placebo to Drug
Subjects will begin treatment on placebo then crossover to study drug.
Intervention: Terbinafine Tablets (Drug)
Placebo to Drug
Subjects will begin treatment on placebo then crossover to study drug.
Intervention: Laboratory Testing (Diagnostic Test)
Drug to Placebo
Subjects will begin treatment on study drug then crossover to placebo.
Intervention: Terbinafine Tablets (Drug)
Outcomes
Primary Outcomes
Change in BASDAI score
Time Frame: 16 weeks
BASDAI score after the completion of 16 weeks of terbinafine treatment versus the BASDAI score after 16 weeks on placebo. Benefit is defined by a reduction of BASDAI score of 2 or more.
Secondary Outcomes
No secondary outcomes reported
Investigators
Atul Deodhar
Professor
Oregon Health and Science University